The safety and pharmacokinetics of rimantadine administered by small-particle aerosol were assessed in healthy adults and adults with acute influenza virus infection. Aerosolized rimantadine delivered at a concentration of 40 ,Ig/liter of air was associated with nasal burning and irritation in normal volunteers. A concentration of 20 ,ug/liter of air was well tolerated for up to 12 h by normal volunteers and was not associated with any changes in pulmonary function, as measured by routine spirometry, plethysmography, or diffusion capacity of carbon monoxide. Mean peak levels of drug in serum were approximately 10-fold lower after 12 h of aerosol administration than they were after oral administration of 200 mg (29.7 versus 255 ng/ml, respectively), while mean nasal wash levels were approximately 100-fold higher (6,650 versus 66.6 ng/ml, respectively). Elimination half-lives were similar after both aerosol and oral administration (24.1 and 25.2 h, respectively), and rimantadine urinary excretion was <1% per 24 h in both groups. Twenty micrograms of aerosolized rimantadine per liter of air given 12 h daily for 3 days to nine adults with acute influenza virus infection was well tolerated. Levels in plasma after 12 h of aerosol inhalation were similar to those in normal volunteers, but were higher at the end of the third treatment than they were at the end of the first treatment (88.3 versus 47.9 ng/ml, respectively). Thus, rimantadine delivered via small-particle aerosol at a dose of 20 jig/liter of air was well tolerated in normal volunteers and in those with acute influenza and was associated with high local concentrations.
The safety and pharmacokinetics of rimantadine administered by small-particle aerosol were assessed in healthy adults and adults with acute influenza virus infection. Aerosolized rimantadine delivered at a concentration of 40 ,Ig/liter of air was associated with nasal burning and irritation in normal volunteers. A concentration of 20 ,ug/liter of air was well tolerated for up to 12 h by normal volunteers and was not associated with any changes in pulmonary function, as measured by routine spirometry, plethysmography, or diffusion capacity of carbon monoxide. Mean peak levels of drug in serum were approximately 10-fold lower after 12 h of aerosol administration than they were after oral administration of 200 mg (29.7 versus 255 ng/ml, respectively), while mean nasal wash levels were approximately 100-fold higher (6,650 versus 66.6 ng/ml, respectively). Elimination half-lives were similar after both aerosol and oral administration (24.1 and 25.2 h, respectively), and rimantadine urinary excretion was <1% per 24 h in both groups. Twenty micrograms of aerosolized rimantadine per liter of air given 12 h daily for 3 days to nine adults with acute influenza virus infection was well tolerated. Levels in plasma after 12 h of aerosol inhalation were similar to those in normal volunteers, but were higher at the end of the third treatment than they were at the end of the first treatment (88.3 versus 47.9 ng/ml, respectively). Thus, rimantadine delivered via small-particle aerosol at a dose of 20 jig/liter of air was well tolerated in normal volunteers and in those with acute influenza and was associated with high local concentrations.
Small-particle aerosol (SPA) delivery of antiviral agents was evaluated for the treatment of viral respiratory tract infections. This method of drug administration usually results in higher concentrations of drug at the site of infection than systemic administration does, may decrease or ameliorate systemic toxicities seen after systemic administration, and has been more effective than the systemic administration of antiviral agents in murine (31) and ferret (9) animal models of acute influenza virus infection. SPA delivery of antiviral agents has also been effective in the treatment of human respiratory viral diseases (13, 14, 17, 22, 24, 28) .
Rimantadine has better antiviral activity against some influenza A virus strains than amantadine does (5), is better tolerated when taken orally (8) , and is effective as a prophylactic (8, 35) and therapeutic (20, 26, 30, 34, 35) agent in influenza A virus infections. Hayden et al. (22) have previously reported the use of rimantadine delivered by ultrasonic nebulizer in subjects given an attenuated influenza A virus; except for minor complaints, the drug was well tolerated. No pharmacokinetic data were reported.
Although the combination of amantadine or rimantadine with ribavirin has been shown to have additive or synergistic activity in vitro (6, 21) and when administered systemically in a murine model of acute influenzal pneumonia (11, 33) , only the combination of ribavirin and amantadine administered via SPA has been examined in an animal (murine) model and has been found to be more effective than singleagent therapy (33) . Similar studies have not yet been done in humans. Because of its greater activity in vitro, rimantadine would be a logical choice for study in combination with ribavirin in humans. However, before the evaluation of SPA * Corresponding author. delivery of combined ribavirin and rimantadine therapy for acute influenza can be tested, the safety of rimantadine SPA delivery needs further evaluation. The purpose of this study was to evaluate the safety, tolerability, and pharmacokinetics of rimantadine when delivered by SPA.
(Preliminary data from this study were (25) . The distribution of deposition of an aerosol generated from this nebulizer was determined previously; approximately 62% of the delivered dose would be deposited in the nasopharynx, 18% would be deposited in the tracheobronchial tree, and 20% would be deposited in the alveoli (25) .
Safety evaluation in normal healthy adults. Twenty-one normal, healthy volunteers (ages, 22 to 12 h on the following 2 days. Two investigators kept logs of the time spent in the volunteers' rooms, and drug levels in plasma were measured daily at the end of each day's aerosol inhalation. Thereafter, drug levels in plasma were determined in one investigator weekly for 2 weeks.
Drug levels. Plasma, urine, and nasal wash specimens were assayed for rimantadine by gas chromatography plus mass spectrometry (TexMS Analytical Services, Houston, Tex.) by previously described methods (10) . Deuterated rimantadine served as an internal standard. The ratio of peak heights and concentrations of known calibration standards were used to generate a standard curve by using weighted (1/y2), nonlinear regression; drug concentration of unknown samples could be calculated from these ratios. Drug concentrations were assayed over a range of 5 to 500 ng/ml. The interassay variability for plasma levels was 1.2% relative standard deviation, and the intraassay variability was 4.5% relative standard deviation.
Pharmacokinetic analysis. The elimination rate constant (kel) was calculated from the slope of the log-linear portion of the decay of the rimantadine plasma concentration-versustime curve. All slopes were calculated by linear regression of the natural logarithm of concentration against time. The area under the curve from initiation of the dose (time zero) to infinity (AUC,_) was calculated by the LaGrange method by using the LAGRAN computer program (27) . From kei and AUC_, the following parameters were calculated for rimantadine disposition for each subject: elimination half-life = 0.693/kel; total plasma clearance (CL) = F. dose/AUCO , VOL. 34, 1990 40 ,ug/liter of air for 15 min to 4 h; mean respiratory symptom scores were significantly higher after rimantadine SPA than after placebo inhalation (Table 1) . Nasal irritation was the only symptom that occurred significantly more often after rimantadine inhalation than after placebo inhalation (9 of 10 versus 0 of 10 subjects, respectively, P = 0.0001; Fisher two-tailed exact test). The irritation increased in severity with increasing duration of inhalation, with three of four volunteers in the 4-h group reporting severe irritation. One volunteer ceased aerosol exposure after 50 min because of nasal irritation.
When PBS was used as a diluent at the same rimantadine aerosol concentration (40 pug/liter of air), the mean respiratory symptom scores remained higher compared with the scores obtained with placebo ( (Table 2) . One volunteer had a significant decrease in FEV1 after both rimantadine and placebo SPA inhalation; however, the volunteer had no subjective complaints, and no wheezing was noted on auscultation of the lungs.
Safety evaluation in adults with acute influenza. Three-day SPA inhalations of rimantadine from a reservoir concentration of 2 mg/ml were well tolerated by the nine volunteers with acute influenza. There was more nasal irritation in the rimantadine treated group than in the placebo group (6 of 9 versus 0 of 9 subjects, respectively; P = 0.009, Fisher two-tailed exact test). However, the irritation was mild and short-lived (duration of less than 15 Table   3 . The mean rimantadine half-life was 24.1 + 10.9 h for the SPA dose and 25.2 + 3.7 h for the oral dose. The bioavailability of the aerosol dose of rimantadine compared with oral administration was 45.6 ± 10.6% for the five subjects studied. Individual bioavailabilities ranged from 36.7 to 60.8%. If it is assumed that the oral bioavailability of rimantadine is close to 1 (19) , then pharmacokinetic parameters of total clearance and volume of distribution can be calculated from these data and are given in Table 3 . Similar data for the aerosol dose were obtained by correcting the parameters for the fraction of rimantadine reaching the systemic circulation by the aerosol route of administration (bioavailability).
Rimantadine levels in plasma were significantly higher after oral compared with those after SPA administration at each of the time points that levels were measured (Fig. 1) , and mean peak levels in serum were 8.6-fold higher after oral administration (255.0 ± 30.0 versus 29.7 ± 10.8 ng/ml, respectively). Levels of rimantadine in nasal washings at 12 h were almost 100-fold higher after SPA than after oral administration (6,650 ± 2,860 and 66.6 ± 20.4 ng/ml, respectively); rimantadine was still present in nasal secretions 12 h after completion of SPA inhalation in the three volunteers tested (259 + 45 ng/ml). The percentage of rimantadine excreted unchanged in the urine in the first 24 h was <1% in both groups.
The rimantadine levels in plasma were consistently, but not significantly, higher during the first 12 h of aerosol administration in the volunteers with an acute febrile upper respiratory illness compared with those in the normal volunteers (Fig. 1) . Levels of drug in plasma were significantly higher at the end of the third 12-h SPA treatment compared with those at the end of the first 12-h treatment (88.3 ± 44.4 versus 47.9 ± 23.7 ng/ml, respectively; P < 0.01), but they were still one-third of the peak levels seen after oral admin- 34, 1990 trointestinal side effects have been correlated with peak levels in serum (18) . The mean concentration in nasal wash specimens after 12 h of treatment was 6,650 ng/ml. The 50% inhibitory concentration of rimantadine against several influenza A viruses by the plaque reduction assay has previously been reported to be 200 to 400 nglml (16), a concentration which was less than 10% that achieved in the nasal wash specimens after SPA delivery. Exposure of health care workers to drug delivered by the aerosol route is a potential concern. Ribavirin has been reported to be present in the environment when administered by SPA to infants with respiratory syncytial virus infections (7) . In addition, drug was detected in one specimen from a health care worker who was exposed to the aerosol (7). In our study, rimantadine was also found in the environment. However, it was not detected in multiple plasma specimens from the two investigators from whom samples were obtained. The number of room air changes per hour was higher than the minimum number (two) recommended for patient rooms (1), and drug levels in room air may be higher under other conditions. The importance of this level of drug exposure to health care workers remains to be determined in future studies.
Resistance to rimantadine after oral administration has been reported in several recent studies (4, 15, 29) . The emergence of rimantadine resistance was not examined in this study. Although the clinical significance of rimantadine resistance remains to be determined, it is possible that the use of combination therapy (rimantadine plus ribavirin) may prevent resistance from emerging since strains that are resistant to ribavirin have not been reported (32) .
Rimantadine SPA at a concentration of 20 ,ug/liter of air appears to be safe and well tolerated by both healthy volunteers and those with acute influenza. These studies suggest that an aerosol concentration of 20 ,ug/liter of air is near the maximal tolerable dose. The pharmacokinetics suggest that a lower reservoir concentration of rimantadine could be used to achieve levels in the mucosa greater than the 50% inhibitory concentration of most influenza A viruses; the mild local toxicity could then be decreased even further.
Because of its efficacy in animal models of pneumonia caused by influenza virus, rimantadine SPA deserves further evaluation for its efficacy in the treatment of naturally acquired influenza A virus infections in humans. Furthermore, evaluation of SPA delivery of the combination of rimantadine and ribavirin in humans should be considered.
